For too long, cancer treatment decisions for older adults were heavily influenced by a single number: their chronological age. However, as beautifully explored in “The Evolution of Geriatric Oncology: From the 90s to Now,” we’ve undergone a profound shift, moving beyond this oversimplified approach to truly personalize care.
The 1990s marked “the awakening,” where the medical community recognized that age and basic activity scores simply didn’t capture the complex health landscape of older cancer patients. They were missing crucial “geriatric syndromes” – everything from subtle functional declines and poor nutrition to multiple medications and mild cognitive impairment. This realization paved the way for a more comprehensive approach.
The 2000s ushered in “the era of prediction.” Rigorous studies, especially prospective cohort studies, demonstrated that a detailed geriatric assessment (GA) could accurately predict who was at higher risk for severe treatment complications. Factors like difficulty with instrumental activities of daily living (IADLs), comorbidities, nutritional status, and polypharmacy proved more predictive of severe chemotherapy toxicity than age alone. This led to the development of practical tools like the CRAG Chemotoxicity Tool, providing data-driven insights for oncologists.
By the 2010s, we entered “the intervention era,” with landmark randomized controlled trials like the GAIN trial proving that GA-guided interventions significantly improved outcomes. Patients receiving tailored support based on their GA results experienced dramatically less severe chemotherapy toxicity, fewer falls, and better quality of life. This compelling evidence led to the 2018 ASCO guidelines, recommending that all adults aged 65 and older considered for chemotherapy undergo a geriatric assessment, cementing GA as a standard of care.
Now, in the 2020s, we are in the era of “implementation, expansion, and refinement.” The focus is on seamlessly integrating GA into busy clinics using screening tools and technology, expanding its application beyond chemotherapy to surgery, radiation, and even newer immunotherapies, and continuously refining interventions for even greater precision. This evolution ensures that cancer care for older adults is not just about treating the disease, but about understanding and supporting the unique individual, aligning treatment with what truly matters most to them.